Current Occupiers

Home to companies that have made a real difference, today scientists, inventors and entrepreneurs work side by side on the development of life-changing drugs within this sustainable environment. Current occupiers include:

Arecor is a UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides

Axol Bioscience specialises in the use of stem cell technology to produce highly validated, human cells and critical reagents such as media and growth supplements.

Camena Bioscience is the developer of pioneering technology that profiles small molecules, such as metabolites, nutrients or medicines in liquid samples.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Domainex is a privately-owned, rapidly-growing drug research company with expertise in expression of disease target proteins, hit discovery, hit-to-lead identification and lead optimisation

Illumina apply innovative sequencing and array technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable a few years ago.

Isomerase Therapeutics is a drug discovery and development company with particular expertise in the discovery and development of optimised microbial natural products.

Oncologica provides precision oncology testing, via its revolutionary targeted sequencing platform to address the growing demand for personalised molecular profiling of patients for targeted therapies.

TLIP (Turnbull Lynch Intellectual Property) are experienced European patent and trademark attorney’s, offering a wide range of services to support clients throughout the innovation process.

Xenovium delivers drug discovery and development projects in partnership with their pharmaceutical and biotech clients.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines in therapy areas including CV and oncology.

Cambridge Epigenetix Cambridge Epigenetix are developing best in class technology and services to make studying DNA methylation as easy as studying DNA sequence.

Cellcentric is a drug discovery company developing small molecule inhibitors for cancer. The company’s primary programme targets an enzyme strongly associated with prostate cancer.

Diagnostics for the Real World (DRW) is committed to tackling some of the world's most serious infectious diseases by making widely available breakthrough point-of care diagnostics.

Evonetix is developing a novel method of manufacturing DNA molecules, using a microchip-based array.

Isogenica operates a biologics discovery service including library supply to the life science industry.

Nodthera NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation.

SAM delivers smart, agile technology across Live Production, Production, Editing & Finishing, Playout & Delivery, Infrastructure & Image Processing, all running under enterprise-wide Management & Workflow automation.

UK Science Park Association is the authoritative body on the planning, development and creation of Science Parks that facilitate the development of innovative, knowledge-based companies.

Contact Us

Chesterford Research Park,
Little Chesterford, Cambridge CB10 1XL

Telephone: 01799 532 252
Site designed by Limewash